XML 58 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets
 12 Months Ended
Dec. 31, 2013
Intangible Assets  
Intangible Assets

8. Intangible Assets

        Intangible assets, which consist of registrational and launch-related milestone fees paid or owed to GSK, were as follows:

 
   December 31, 2013  
(In thousands)
  Weighted
Average
Remaining
Amortization
Period
(Years)		   Gross
Carrying
Value		   Accumulated
Amortization		   Net Carrying
Value		  

FDA approval and launch of BREO® ELLIPTA® in the U.S. 

     15.7   $ 60,000   $ (632 ) $ 59,368  

MHLW approval and launch of RELVAR® ELLIPTA® in Japan

     14.9     20,000     (111 )   19,889  

European Commission approval of RELVAR® ELLIPTA®

     15     15,000     —     15,000  

FDA approval of ANOROTM ELLIPTATM in the U.S. 

     15.2     30,000     —     30,000  
                     
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total intangible assets

         $ 125,000   $ (743 ) $ 124,257  
                     
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
                     

        Additional information regarding these milestone fees is included in Note 3 "Collaborative Arrangements." Amortization expense for the BREO® ELLIPTA® intangible asset for the U.S. region and the RELVAR® ELLIPTA® intangible asset for the Japan region began in the fourth quarter of 2013 and is recorded as a reduction in revenue from collaborative arrangements. Estimated annual amortization expense of intangible assets is $7.1 million for 2014, $8.1 million for each of the years from 2015 to 2018 and $84.7 million thereafter.